Raymond James Financial Services Advisors’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-9,197
Closed -$246K 3343
2023
Q3
$246K Sell
9,197
-10,452
-53% -$357K ﹤0.01% 2791
2023
Q2
$728K Buy
19,649
+10,380
+112% +$362K ﹤0.01% 2115
2023
Q1
$289K Buy
9,269
+743
+9% +$23.9K ﹤0.01% 2663
2022
Q4
$254K Buy
8,526
+416
+5% +$14.9K ﹤0.01% 2694
2022
Q3
$309K Sell
8,110
-9,495
-54% -$476K ﹤0.01% 2549
2022
Q2
$960K Sell
17,605
-7,300
-29% -$401K ﹤0.01% 1867
2022
Q1
$1.55M Buy
24,905
+5,106
+26% +$336K ﹤0.01% 1665
2021
Q4
$1.99M Sell
19,799
-523
-3% -$46K ﹤0.01% 1537
2021
Q3
$1.83M Buy
20,322
+146
+0.7% +$13.3K ﹤0.01% 1536
2021
Q2
$1.86M Sell
20,176
-3,729
-16% -$298K ﹤0.01% 1508
2021
Q1
$2.31M Sell
23,905
-5,697
-19% -$588K 0.01% 1319
2020
Q4
$1.54M Buy
29,602
+143
+0.5% +$5.97K ﹤0.01% 1459
2020
Q3
$1.18M Sell
29,459
-8,086
-22% -$253K ﹤0.01% 1457
2020
Q2
$601K Buy
+37,545
New +$575K ﹤0.01% 1796

Other funds holding FLGT

Raymond James Financial Services Advisors's FLGT Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of Fulgent Genetics (FLGT) in Q4 2023, closing a stake of 9,197 shares — an estimated $246K sold.

Raymond James Financial Services Advisors first reported a position in FLGT in Q2 2020 and held it in 14 quarters. The position peaked at $2.31M in Q1 2021. 196 funds tracked by Wall St. Rank hold FLGT as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining Fulgent Genetics position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 9,197 Fulgent Genetics shares in Q4 2023, an estimated $246K.
  • Raymond James Financial Services Advisors first reported a position in Fulgent Genetics in Q2 2020 and held it in 14 quarters.
  • Raymond James Financial Services Advisors's Fulgent Genetics position peaked at $2.31M in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.